Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT01718353 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: DOCETAXEL (XRP6976)
DRUG: CABAZITAXEL (XRP6258)
DRUG: Prednisone

Sponsor

Sanofi